

Author Index of Volume 5, 1982

Adams D.D. 413
Andres G.A. 357
Atkins R.C. 269
Baldwin R.W. 113
Bonadio J.F. 297
Bottazzo G.F. 433
Brentjens J.R. 357
Brown J.P. 127
Carnegie P.R. 379
Carter R. 175
Chandler J.P. 193
Chiavato L. 433
Clarkson A.R. 321
Cotran R.S. 251
Doniach D. 433
Drebin J.A. 175
Dye E.S. 193
Fidler I.J. 161
Glasgow E.F. 269
Goding J.W. 463
Greene M.I. 175
Hanafusa T. 433
Hancock W.W. 269
Hardy W.D. Jr 75
Harrison L.C. 447
Hellström I. 127
Hellström K.E. 127
Holdsworth S.R. 269
Jablonska S. 33
Killen P.D. 297
Klein E. 63, 147
Klein G. 1
Knight A. 413
Lindstrom J.M. 389
Lomax-Smith J.D. 321
Lutzner M.A. 33, 53
Mackay I.R. 379
Manley S.W.W. 413
Masucci M.G. 63
Melcion C. 297
Mills C.D. 193
Mingari M.C. 477
Mora P.T. 7
Morel-Maroger L. 297, 333
Moretta A. 477
Moretta L. 477
Neale T.J. 221
Noble B. 357
North R.J. 193
Orth G. 33
Pantaleo G. 477
Perry L.L. 175
Poste G. 161
Preud'Homme J.L. 333
Schreiner G.F. 251
Seybold M.E. 389
Seymour A.E. 321
Striker G.E. 297
Thomson N.M. 269
Unanue E.R. 251
Verroust P. 333
Wilson C.B. 221
Woodroffe A.J. 321
Zinkernagel R.M. 107

Subject Index

Acetylcholine receptors (AChRs) 389
-, autoimmune assault 389
-, antibodies to 390
activated macrophages 162
adoptive immunotherapy, radiation-facilitated 214
alcoholic liver disease 322
amyloidosis 339
antibodies to lymphocyte surface receptors 463
antigenicity 109
antigens, "planted" or trapped 237
anti-I-A antisera 182
antigen receptors 466
atopy 454
-, autonomic function 455
autoimmunity 443
azobenzenearsonate (ABA) 177

B lymphocyte dysfunctions 91
B lymphocytes, EBV infected 63
Beta-adrenergic receptors 454
blocking antibodies to TSH receptors 442
Bowenoid papulosis 48
brush border of proximal tubules 363

Cell lysis, antibody-mediated 15
-, T cell-mediated 16
cellular immunity 251
circulating immune complexes (CIC) 94
-, cellular responses 303
collagen type VI 227
complement 93, 395
-, nephritis 370
complement-mediated lysis 464
concomitant immunity, T cell-mediated suppression 206
condylomas 44
cryoglobulinemia 347
cytolytic T lymphocytes 481

Diabetes mellitus, insulin receptors 448
DNA transfection 186
dysproteinemia, renal lesions 333

Epidermodysplasia verruciformis (EV) 41, 42
extracellular matrix 299
extracorporeal immunosorption 100

FcγR 480
feline leukemia virus (FeLV) 75
-, neutropenias 90

feline oncornavirus-associated cell-membrane antigen (FOCMA) 78

Glomerular antigenic determinant, immune complex 252
glomerular basement membrane (GBM) 222
-, Goodpasture's syndrome 222
glomerular injury, macrophages 252
-, mononuclear cell involvement 252
-, non-immune 307
glomerular phagocyte, Ia+, mesangium 261
glomerulonephritis 221
-, anti-glomerular antibodies 252
-, anti-GBM antibody induced 222
-, complement 252
-, experimental 251
-, immune complexes 252
-, immunopathogenic mechanisms 358
-, lymphocytes 251
-, macrophages 256
-, macrophage identification 270
-, mesangial immune complex 260
-, mesangial IC, lymphocytes 260
-, mesangial proliferative 322
-, monocytes 251, 256
-, pathogenesis of monocyte infiltration 257
-, platelets 252
-, T cell-dependent immunity 289
glomerulitis, human, cellular immune mechanisms 269, 289
-, proliferative 255
-, -, mononuclear cell infiltration 255
-, -, neutrophil infiltration 255
-, -, proteinuria 255
glomerulus, humoral-mediated injury 252
-, normal 298
goitrogenesis 443
Goodpasture's syndrome, GBM 222
Goodpasture's disease 259
Graves' disease 414, 435

Hamster, tumorigenicity and immunologic changes in 23
helper T cells 480
Henoch-Schönlein purpura 322
Heymann's nephritis 365
-, active and passive 234
histocompatibility antigens 424
-, thyroid disorders 443
H gene theory 425
HLA-D related gene 482
hormone receptors, autoantibodies to 447
human tumor-associated antigens (TAA) 127

Ia antigens 477, 482
IgA nephropathy 322
immune cell deficiency diseases, FeLV-induced 82
immune complexes 367
-, circulating 302
immune complex disease 94
immune complex glomerulonephritis 97
immune recognition 114
immune surveillance 107
-, blind spots 109
immunity, cell-mediated 63
immunocompetent syngeneic host 19
immunofacilitation 195
immunofluorescence 38
immunogenicity 109
immunological adjuvants 118
immunoperoxidase technique 40
immunopotentiation 201
-, therapeutic 203
immunostimulation 116
immunosuppression, oncogenic viruses 75
immunotherapy, adoptive 205, 214
infectious mononucleosis 63, 68
insulin receptors, diabetes mellitus 448
interferon 93
interstitium 357

LATS-protector 415
liposomes 166
liver disease, alcoholic 322
long-acting thyroid stimulator (LATS) 415
Ly-1 and Ly-2 antigens 467
lymphocyte-mediated cytotoxicity 149
lymphocyte surface receptors, antibodies to 463
lymphoid atrophy 85
lymphokines 162

Macrophages 119, 251
-, activated 162
macrophage dysfunctions 92
melanoma antigens 129
mesangial cells, Ia+, Ia- 262
mesangial cells, mononuclear phagocyte 264
-, -, Ia+ phagocyte 264
mesangium 324
metastases 161
monoclonal antibodies 115, 129, 477, 480
monoclonal antibodies to AchRs 395
mononuclear phagocytes 274
myasthenia gravis, experimental autoimmune 390
myeloblastopenia 89
myeloma 335
myxoedema, primary 438

N-acetyl-L-alanyl-D-isoglutamine (MDP) 162
natural killer (NK) cells 150
nephritis, complement system 370
-, mesangial IgA, Circulating immune complexes 323
-, neutrophil-associated proteinuria 253
-, nephrotoxic 256
-, -, decompensation 257
-, -, Fc receptors 258
-, -, helper T cells 259
-, -, lymphocytes 259
-, -, monocytic infiltrate 257
-, -, proteinuria 256
-, -, x-irradiation 256
-, nephrotoxic serum 253
neutropenia, FeLV-induced 90
NK cells 119
non-toxic nodular goitre 433, 436

Papillomavirus 33
-, oncogenic potential 35
pathogenetic mechanisms 463
polyoma tumor 178

Regional immunotherapy 118
renal disease, viral infections 304
retrovirus 76

Serum sickness 240, 255
specific immunotherapy 116
staphylococcus aureus Cowan I 96
suppressor T cells 178, 210
surface markers 477
SV40 7
systemic lupus erythematosus 322

T antigen 14
T cell clones 481
T cell dysfunction 91
T lymphocytes, surface markers 478
-, cytolytic 481
T lymphocyte subsets 479
thyroid disorders, HLA antigens 443
thyroid-growth-immunoglobulin (TGI) 434
-, cytochemical bioassay 434
thyroid-stimulating autoantibodies, receptor assay 418
thymic atrophy 84
thyrotoxicity 435
thyrotrophin (TSH) 413, 434
-, receptor heterogeneity 421
TSH receptors, blocking antibodies 442
-, monoclonal antibodies to 441
-, as an autoantigen 414
transferrin receptor 470
transformation, SV40-induced (of cells) 8
transplantation rejection (TSTA) 16

tubular basement membrane (TBM) 358
tubules 358
tubulointerstitial nephritis 357
tumor antigens 115, 177
tumor immunity 176
tumor immunology 147
tumorogenicity 14

tumor regression, endotoxin induced 195
tumor-specific immunity 198

Ultra-violet radiation (UV) 181

Waldenström's macroglobulinemia 346
warts 37





Springer Seminars in Immunopathology

Peter A. Miescher, Geneva
Hans J. Mueller-Eberhard, La Jolla

Volume 5 1982

Advisory Board

B. Benacerraf, Boston, MA	R. Krause, Bethesda, MD
M. D. Cooper, Birmingham, AL	H. G. Kunkel, New York, NY
F. J. Dixon, La Jolla, CA	P. Lachmann, Cambridge
K. Eichmann, Heidelberg	P. H. Lambert, Geneva
G. Klein, Stockholm	J. B. Natvig, Oslo



Springer International

Springer Seminars in Immunopathology

With the acceptance of the manuscript for publication the exclusive copyright for all languages and countries, including the right for photomechanical and any other reproduction, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Authors of this journal can benefit from library and photocopy fees collected by VG WORT if certain conditions are met. If an author lives in the Federal Republic of Germany or in West Berlin it is recommended that he contacts Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestrasse 49, D-8000 München 2, for detailed information.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Contents of Volume 5, 1982

Number 1 issued in August 1982

Immunopathology of Virally Induced Tumors II

Guest Editor: G. Klein

- 1 **G. Klein:** Introduction
- 7 **P. T. Mora:** The Immunopathology of SV40-Induced Transformation
- 33 **S. Jablonska, G. Orth, M. A. Lutzner:** Immunopathology of Papillomavirus-Induced Tumors in Different Tissues
Addendum: M. A. Lutzner: Immunopathology of Papillomavirus-Induced Warts and Skin Cancers in Immunodepressed and Immunosuppressed Patients
- 63 **E. Klein, M. G. Masucci:** Cell-Mediated Immunity Against Epstein-Barr Virus Infected B Lymphocytes
- 75 **W. D. Hardy Jr.:** Immunopathology Induced by the Feline Leukemia Virus
- 107 **R. M. Zinkernagel:** How to Escape Immune Surveillance?

Indexed in Current Contents

Number 2 issued in September 1982

Mechanism of Host Resistance in Cancer

Guest Editor: R. W. Baldwin

- 113 **R. W. Baldwin:** Introduction: Manipulation of Host Resistance in Cancer Therapy
- 127 **K. E. Hellström, I. Hellström, J. P. Brown:** Human Tumor-Associated Antigens Identified by Monoclonal Antibodies
- 147 **E. Klein:** Lymphocyte-Mediated Lysis of Tumor Cells *in vitro*: Antigen-Restricted Clonal and Unrestricted Polyclonal Effects
- 161 **I. J. Fidler, G. Poste:** Macrophage-Mediated Destruction of Malignant Tumor Cells and New Strategies for the Therapy of Metastatic Disease
- 175 **J. A. Drebin, L. L. Perry, R. Carter, M. I. Greene:** Regulation of the Immune Response to Antigens on the Malignant Cell Surface
- 193 **R. J. North, E. S. Dye, C. D. Mills, J. P. Chandler:** Modulation of Antitumor Immunity — Immunobiologic Approaches

Indexed in Current Contents

Number 3 issued in December 1982

Kidney Disease

Guest Editor: C. B. Wilson

221 **T. J. Neale, C. B. Wilson:** Glomerular Antigens in Glomerulonephritis

251 **G. F. Schreiner, R. S. Cotran, E. R. Unanue:** Macrophages and Cellular Immunity in Experimental Glomerulonephritis

269 **R. C. Atkins, S. R. Holdsworth, W. W. Hancock, N. M. Thomson, E. F. Glasgow:** Cellular Immune Mechanisms in Human Glomerulonephritis: The Role of Mononuclear Leucocytes

297 **P. D. Killen, C. Melcion, J. F. Bonadio, L. Morel-Maroger, G. E. Striker:** Glomerular Response to Immunologic Injury, Studies on Progression

321 **A. J. Woodroffe, A. R. Clarkson, A. E. Seymour, J. D. Lomax-Smith:** Mesangial IgA Nephritis

333 **P. Verroust, L. Morel-Maroger, J. L. Preud'Homme:** Renal Lesions in Dysproteinemias

357 **J. R. Brentjens, B. Noble, G. A. Andres:** Immunologically Mediated Lesions of Kidney Tubules and Interstitium in Laboratory Animals and in Man

Indexed in Current Contents

Number 4 issued in December 1982

Cell Surface Receptors

Guest Editor: I. R. Mackay

379 **P. R. Carnegie, I. R. Mackay:** Evolution of Studies on Antireceptor Antibodies and Diseases

389 **M. E. Seybold, J. M. Lindstrom:** Immunopathology of Acetylcholine Receptors in Myasthenia Gravis

413 **S. W. W. Manley, A. Knight, D. D. Adams:** The Thyrotrophin Receptor

433 **D. Doniach, L. Chiovato, T. Hanafusa, G. F. Bottazzo:** The Implications of "Thyroid-Growth-Immunoglobulins" (TGI) for the Understanding of Sporadic Nontoxic Nodular Goitre

447 **L. C. Harrison:** Autoantibodies to Hormone Receptors

463 **J. W. Goding:** Biological Effects of Antibodies to Lymphocyte Surface Receptors

477 **M. C. Mingari, A. Moretta, G. Pantaleo, L. Moretta:** Surface Markers of Resting and Activated Human T Cells. Functional Implications and Experimental Limits

